Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Acute Gout
NCT03636373Phase 4Terminated
- Sponsor
- Rutgers University
- Start
- Oct 2019
- Primary completion
- Aug 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of etanercept in gout (2 arms), sponsored by Rutgers University. Primary endpoint: Joint Pain Intensity in the Most Affected Joint at 72 hours. Started Oct 2019; status: terminated.
02
Drugs
etanercept
03
Conditions
gout
Beyond the preview
Go deeper on NCT03636373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636373.